Hospital Clinical Chemistry and Immunodiagnostics Market - Global Markets & Advanced Technologies

Hospital clinical chemistry refers to the area of clinical pathology related to the analysis of body fluids such as blood, urine, etc. and immunodiagnostics is a diagnostic method based on antigen-antibody reaction. There have been remarkable advances in the field of clinical chemistry and immunodiagnostics, resulting into potential diagnostic platform and technologies such as molecular diagnostics, spectrophotometry, electrophoresis, measurement of enzyme activities, and separation of molecules. Clinical chemistry and immunodiagnostics play a critical role to aid the clinicians in the prevention, diagnosis and treatment of diseases. Diseases generally diagnosed with the help of clinical chemistry include viral and bacterial infection, diabetes, thyroid, kidney failure, heart problems, cystic fibrosis in new born babies and screening for illegal drug use.

Based on types of tests, the hospital clinical chemistry and immunodiagnostics market can be segmented as follows:

• Clinical chemistry
• Routine chemistry: It is generally used for the analysis of blood for various tests such as kidney function tests
• Special chemistry: This branch of clinical chemistry uses advanced methods such as electrophoresis
• Drug monitoring: It measures the therapeutic drug medication level in order to determine the right dosage
• Endocrinology: This clinical chemistry test involves the study and diagnosis of endocrine disorders
• Toxicology: It involves the study of drugs of abuse
• Urinalysis: Urinalysis refers to the analysis of urine sample to diagnose a wide array of diseases
• Immunodiagnostics
• Enzyme-Linked ImmunoSorbent Assay or ELISA: ELISA is a commonly used laboratory test that uses a solid-phase enzyme immunoassay (EIA) to detect antibody in the blood sample
• Radioimmunoassay: It is an in vitro assay technique used for the measurement of hormone levels in the blood. One of the examples of radioimmunoassay is the RAST test (radioallergosorbent test) which is used to detect the presence of causative allergen for a specific allergy.

Based on geography, the hospital clinical chemistry and immunodiagnostics market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). North America holds a leading position in the market followed by Europe. The prime factors which are responsible for the growth of hospital clinical chemistry and immunodiagnostics market in these regions are increasing prevalence of various diseases among the population, and the growing need for technologically advanced diagnostic tests. Moreover, major breakthrough developments in clinical chemistry and immunodiagnostics have resulted in reduction of immunoassay duration and complexity, thereby spurring the growth of the market. Asia Pacific is one of the lucrative markets for the growth of hospital clinical chemistry and immunodiagnostics market due to various emerging economies. Factors which would contribute towards the growth of the market in Asia Pacific are growing need of the population for rapid and cost-effective immunoassay procedures and novel diagnostic platforms. Cost-savings can be achieved with the aid of clinical chemistry and immunodiagnostics due to highly centralized operations and automated data analysis.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6925

Various advances in diagnostic technologies, automation and huge competition in the hospital clinical chemistry and immunodiagnostics market is paving way for a number of opportunities. A number of top companies operating in the market are Abbott, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Siemens AG, Danaher Corporation, Bio-Rad Laboratories, Inc., Alere and others.

Single-Dose Therapy Market Segment Forecast up to 2024

Single-dose therapy can be defined as single drug, or a combination of two or more active pharmaceutical ingredients (API) to be administered in a single dosage form. The drugs combined in the single dosage form contributes to the synergistic effects claimed by each of the drug. The number of doses of the single dose therapy can be increased or decreased, but the therapy does not involving altering of API proportion in the dosage form. These are administered in the form of a vial, capsules, tablets or patch.

Single-dose therapy market can be segmented based on disease indication, application, distribution channel, and geography. Based on disease indication, the market can be segmented into cancer, HIV/AIDS, sexually transmitted diseases, neurological disorders, psychological disorders, and microbial infections, among others. On the basis of application, single-dose therapy market can be segmented into human health and animal health. Hospitals, ambulatory centers, clinics, and pharmacies form the major distribution channels for the market. Based on geography, the market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

Increasing demand due to the synergistic effects provided by the combined fixed dose API’s administered as a single dose is the major driver for the single-dose therapy market. Further, the simpler treatment regime, convenience of administration, and the cost saving offered by single-dose therapy are also expected to drive the market growth. Additional benefits include the combined pharmacokinetics of the component drugs employed in the single dose, and enhanced medication compliance. However, the dosage of the APIs in the single-dose cannot be modified according to the patient requirements, which might negatively impact the growth of the market. In addition, the adverse side effects caused by the component drugs, the allergic reactions from any of the component drugs in the single dose therapy cannot be avoided, which might have an impact on the patient health, and a negative effect on the market growth. Also, the growing over-the-counter sale of various non-approved fixed dose combinations administered as single dose, would adversely affect the market.

Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13718

The increasing incidence of sexually transmitted diseases (STDs), and various forms of cancer in all the geographies would drive the demand for single-dose therapies and contribute to the growth of the market. Geographically, North America is the largest market for single-dose therapy, followed by Europe. The growing geriatric population, and increased focus on research and development of effective single dose therapies has been driving the use of single-dose therapies. In addition, the growing FDA approvals of new single-dose therapies would contribute to the growth of the market. For instance, in November 2015, the U.S. FDA approved Genvoya, a single dosage form of various combination drugs for the treatment of HIV-1 infection. Asia Pacific is expected to record significant growth during the forecast period, attributed to the growing economy in the emerging markets of Asia Pacific, growing awareness among people and the increasing geriatric population.

The leading players in the single-dose therapy market include Allergan plc, AstraZeneca plc, Bayer AG, BioCryst Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Merck & Co., Novartis AG, Pfizer, Inc., and Sanofi S.A., among other significant global market players.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Polymerase Chain Reaction (PCR) Market - An insight on the important factors and trends influencing the market

PCR techniques have paved the way for innovation in life sciences research and molecular diagnostics through its most potential features such as absolute detection and quantification of genetic materials such as DNA and RNA. Researchers are able to quantify and analyze rare alleles and point mutations using advanced PCR systems such as digital PCR. Currently, the market players are engaged in developing PCR systems with enhanced capabilities such as broad menu of tests, higher sensitivity and specificity. Other major advances associated with the PCR include shorter turnaround times (PCR cycling time), higher productivity and automated workflow; thereby ensuring efficient detection and amplification of genetic materials with accurate results. The market is witnessing significant advances in the design of PCR platforms shifting from conventional standard PCR to real time and digital PCR systems to efficiently detect pathogenic microbes such as mycobacterium tuberculosis bacteria and influenza viruses. For instance, introduction of QX200 Droplet Digital PCR System by Bio-Rad provides a broad menu of molecular diagnostic tests and enhanced workflow to enable overall cost reduction and eliminate the need for multiple systems. The global PCR market is valued at USD 6,065 million in 2013 and is expected to reach USD 9,621.0 million with the CAGR of 6.6% during the forecast period of 2014 to 2020.

Although, the use of PCR has been mostly confined to research institutions, pharmaceutical and biotechnology industries, currently, the market has seen an increasing preference of PCR in the commercial diagnostic laboratories and hospitals due to precise diagnoses of life-threatening diseases such as cancer and Ebola. Multi-chain diagnostic laboratories are currently focusing on expanding their operations in less developed areas by acquiring standalone laboratories with minimal infrastructure. Therefore, a strong demand for compact and portable PCR with high reliability and sensitivity is created. All these features along with high affordability are expected to provide impressive growth opportunities for PCR market.

The PCR market is broadly classified on the basis of product segments, end-users and application areas. Among the product segments, reagents and consumables remain the most widely used segment with the largest share in the net sales across various companies, considering the global sales of USD 4,072.2 million in 2013. Among various end-users of PCR, academics and research organization was accounted for the largest market share of overall market in 2013, followed by clinical diagnostic labs and hospitals segment. However, clinical diagnostics segment is likely to grow at an impressive pace during the forecast period of 2014 to 2020. Among the PCR applications area, the life sciences segment is the largest application area covering more than 48% of the total PCR market followed by clinical diagnostics segment with 33% of the market share. The majority market share by the life sciences segment corresponded to its wider acceptance in the cancer research, which is also amongst the oldest segments of PCR application.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=830

Geographically, North America accounted for the largest share of global PCR market in 2013 followed by Europe. These two regions are expected to retain their position throughout the forecast period 2014 to 2020. This is majorly attributed to the presence of technologically sophisticated diagnostic laboratories along with wider acceptance of novel assay technologies. The North American region was among the first to approve and implement the PCR based assays for diagnosis of infectious diseases such as HIV. The Asia Pacific region on the other hand is expected to represent the highest growth rate during the forecast period. This can be attributed to the growing investment in research and development in the region by the Government and private investors. China for example, is at present the world’s second largest investor in research and development according to the World Bank data.

The overall PCR market is consolidated and characterized by the presence of few established players accounting for more than 50% of the total market share. Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Agilent Technologies and Sigma-Aldrich Corporation Beckman Coulter, Bio-Rad, Becton Dickinson and QIAGEN are some of the key players operating in this market.

Medical Plastics Market Witnesses Rising Demand and Investment from R&D Activities

Transparency Market Research holds a large compilation of research reports on the healthcare industry and the medical devices industry. One of the latest titles under the latter is the “Medical Plastics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 – 2018,” which aims to assess the various strengths, weaknesses, opportunities, and restrictions that the market will experience over the given forecast period.

The greatest factor responsible for the growth of the global medical plastics market is the increasing demand for disposable medical devices. A large number of healthcare organizations are insisting on disposable medical devices as they help maintain a better standard of hygiene and prevent the reuse of devices such as syringes and needles. Another driver of the global medical plastics market is the increasing need for better quality plastics that can increase the shelf life of medical devices. Other factors promoting the growth of this market are the increasing trade of medical devices due to relaxing international trade laws and an increase in the overall expenditure on healthcare.

There are also the improvements in the materials themselves that are again pushing the global medical plastics market forward. These include the reduction in weight of the plastics without compromising on durability and the safe use of non-metallic i.e., plastic medical devices around magnetic fields created by medical equipment such as the MRI.

One of the restrictions on the global medical plastics market is the care that needs to be taken in disposing the plastic medical devices. Bodies such as the Healthcare Plastics Recycling Council, or the HPRC are active in this space. The HPRC can provide assistance to medical organizations in managing the safe disposal of medical devices. This is a highly advantageous step for medical bodies towards adhering to the increasingly stringent regulations imposed by governments pertaining to the control of ecological damage caused by unmonitored disposal.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1115

The use of plastics in the healthcare sector spans a wide array of fields, including packaging, in most types of modern medical devices, and especially the disposable medical devices.

From a regional perspective, the U.S. has consistently held the largest share in the global medical plastics market in the recent past. The nation’s dominant position is attributed to its highly advanced healthcare infrastructure, the presence of key global players, and the high medical expenditure coupled with greater awareness of the use of quality medical devices.

The key players in the global medical plastics market include Alcan Packaging, Tekni Plex Corporation, ExxonMobil Corporation, Saint Gobain Performance Plastics, Cyro Industries, Bayer, Du Pont, The DOW Chemical Company, Baxter International, Becton and Dickinson, and BASF SE.

Medical devices outsourcing emerged as cost-effective solution in various disciplines of medicine

The global medical devices outsourcing market is driven by rising demand for quality healthcare services, ongoing developments in the field of medical technology, and parallel operational requirements to cut costs for long term sustainability.The global market, which is seeing a rising trend of services and product outsourcing by leading global players to small and specialized service providers in emerging markets, is broadly categorized into product outsourcing and services outsourcing markets.

The medical devices services market is highly diversified and market leaders are expanding their portfolio to tap the high potential. The global medical devices market can be segmented based on factors such as – Application: Class I medical devices, Class II medical devices, and Class III medical devices, and Services: Product design and development services, Regulatory consulting services, Product testing services, Product implementation services, Product upgrade services, and Product maintenance services. Geographically, the market is segmented into Asia Pacific,Europe, North America, andRest of the World (RoW).

Competition amongst medical device manufacturers and the urge to increase profit margins is driving the demand for medical devices outsourcing. Increased product recalls have also boosted demand for services such as testing services and validation services. Among all the geographic regions,North America holds the largest share of medical devices outsourcing market due to the growing healthcare costs. The high penetration and coverage by medical insurance providers in the region too is further helping to boost the demand for quality healthcare services, forcing industry players to outsource services. The fast developing Asia Pacific market is continuously attracting foreign players to leverage market potential, and as a result, service providers in the region are continuously looking for higher and advanced quality certifications.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=361

Within the medical devices manufacturing industry, orthopedic devices constitute the leading share with cardiology devices quickly catching up as the fastest growing device type being outsourced for manufacturing services. The need for integration of other supportive technologies, such as telecommunications, digital imaging and diagnostics, robotics, and many more is further contributing to the market growth and guiding the entry of players from different industries into the market. By application, Class II devices are the largest market share holder due to moderate associated risks and limited regulatory requirements. However, due to high technical and manufacturing cost containment challenges, product design services form the largest market segment of all other medical device services outsourced. Also, outsourcing is helping companies to focus on other business activities and manage their product life cycles, which again is driving the market growth.

Orthodontic Equipment and Consumables Market - Latest Trends & Insights 2020

The heavily consolidated global orthodontics equipment and consumables market is dominated by Danaher Corporation, DENTSPLY International Inc., and Patterson Companies Inc. According to Transparency Market Research, these three leading players accounted for 63.5% of the orthodontic equipment and consumables market in 2013, with the next two companies collectively accounting for more than 20% of the market.

Apart from the aforementioned market leaders, A-Dec Inc., Midmark Corporation, Ultradent Products Inc., 3Shape A/S, Zimmer Holdings Inc., and Sirona Dental Systems Inc. are among the key manufacturers of orthodontic equipment and consumables.

Increasing Demand for Cosmetic Dentistry Leads to Rising Demand for Orthodontics Equipment

The prime drivers for the global orthodontic equipment and consumables market are the increasing demand for cosmetic dentistry. The high prevalence of malocclusions (incorrect bite) has led to an increase in orthodontic procedures to correct the jaw structure. The increasing demand to improve one’s appearance by altering one’s dental structure has also boosted the demand for orthodontic equipment and consumables.

The booming dental tourism in emerging Southeast Asian countries is another crucial driver for the global orthodontic equipment and consumables market. The ease of traveling to countries that offer advanced medical services at much cheaper rates than in developed countries has led to many Westerners traveling to Southeast Asian dental tourism hubs in recent years. This is likely to remain an influential driver for the global orthodontic equipment and consumables market in the coming years.

On the other hand, the key restraint on the market is the apathy among the general population about dental care. The high costs of advanced orthodontic equipment and consumables are another key constraint acting on the market.

CAD/CAM Systems Exhibiting Robust Growth, Dental Radiology to Retain Dominance

Among the various types of equipment used in orthodontic procedures, dental radiology equipment is the leading contributor to the orthodontic equipment and consumables market. However, CAD/CAM systems have exhibited a robust growth rate since the early part of the decade and have become increasingly important in orthodontics thanks to the steady incorporation of progressive technological advancements. Among orthodontic consumables, brackets have always been the dominant segment, and are likely to remain the leading contributor to the orthodontic equipment and consumables market in the coming years.

Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2357

Geographically, North America is the dominant market for orthodontic equipment and consumables, with a revenue of US$3.3 bn expected in 2016, and is likely to retain its lead in the coming years. Europe and Asia Pacific also remain key contributors to the global orthodontic equipment and consumables market, with the latter expected to exhibit by far the highest CAGR of all regional segments in the 2014-2020 forecast period – 10.9%.

The global orthodontic equipment and consumables market is expected to be valued at close to US$7.8 bn by 2016 and further rise to US$11 bn by 2020. The information presented in this review is based on a Transparency Market Research report titled ‘Orthodontic Equipment and Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.’

Postmenopausal Hormone Therapy Market Dynamics and Opportunities Report by Transparency Market Research

Post menopause is the period occurred after menopause followed by various syndromes like vaginal dryness, hot flashes, etc. During this period level of estrogen and progestin falls significantly leading to even serious complications like osteoporosis. The worldwide market for Postmenopausal Hormone Therapy is gaining moment substantially. This rising demand for Postmenopausal Hormone Therapy is due to increasing level of awareness about menopausal symptoms and its treatment. Another factor is growing population of post-menopausal women. Postmenopausal Hormone Therapy includes replenishment of body level of estrogen and progestin hormones in women through external intake of hormones. Thus, it help in treating the menopausal symptoms. It decreases the symptoms like vaginal dryness, hot flashes, disturbed sleep, night sweats and etc. The Postmenopausal Hormone Therapy helps in prevention of osteoporosis and hot flashes caused due to depletion of estrogen and progestin level in body. The Postmenopausal Hormone Therapy comprises of natural as well as synthetic estrogens. In order to enhance the menopausal treatment, it is also given in combination with progesterone.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13568

The treatment for post – menopausal syndrome is generally treated with sequential or continuous schedules through various doses of estrogen, progestin or combination of both. Despite of existing controversy and confusion about the safety profile of the postmenopausal hormone therapy, the market for the postmenopausal hormone therapy has recorded positive inclining growth due to growing demand. The development of postmenopausal hormone therapy with respect to driving demand leads to introduction of highly safe treatment options to patients which include development of novel drug delivery system like vaginal estrogen drugs and transdermal estrogen patches. Low dose postmenopausal hormone therapy are used in order to address the backdrop caused due to safety issues. The non-hormonal treatment has comparatively least efficacy to produce optimum results, hence the postmenopausal hormone therapy market is observed to grow significantly.

However, the major retarding factors to the market include the affordability to the therapy. The cost for postmenopausal hormone therapy approximately revolves around US$ 10,000 per annum, and thus incurring a major burden on the patients’ pocket. Thus the population from developing and under – developed countries faces a challenge of affordability for the postmenopausal hormone therapy. The post treatment risk of cervical cancer and coronary disease are another restraining factors for the market. Approved recognition of the products related to postmenopausal hormone therapy in compounding pharmacies particularly from developed countries is another deterring factor. However the opportunity for the market is the introduction of the product targeting the cardiovascular disease prevention.

The Postmenopausal Hormone Therapy market can be segmented by product, by therapy, by dosage form, by route of administration, by end-user and by geography. In the terms of product, the postmenopausal hormone therapy is classified into patches, tablets, creams, suppositories, and injections. The tablet formulation comprises the largest market share of the total postmenopausal hormone therapy market. However, due to growing concern of safety and long-term therapy the market for the patches are growing at much faster compound annual growth rate. Based on the therapy, the market is segmented into individual progestin, estrogen and combination therapies. The majority of market is occupied by estrogen therapy across the world.

Based on the route of administration, the postmenopausal hormone therapy market is classified into oral, topical and subcutaneous implants. Due to high safety, oral administration has been the preferred choice of option for the patient. However, introduction of novel drug delivery system has driven the market for topical and subcutaneous products as well. In the terms of end-user, the target population are the women suffering from menopause. However, the treatment is influenced by the physician/ gynecologist, the target end-users are hospitals and specialty clinics.

Geographically, North America occupies the largest market share followed by other developed region like Europe. The United States accounts for a major share of the global market. The high awareness level and high purchasing power in this region led the market of postmenopausal hormone therapy for expansion significantly. However, the same factor of affordability has restrained the markets in developing regions. Despite of this, Asia Pacific has shown striking increase in its growth rate for the postmenopausal hormone therapy market. Rising population, increase in disposable income, and increase in awareness level are some key factors driving the Asia Pacific Market. Due to this factors, the Asian market is observing high number of new entrants compared to those in developed regions.

The Major players reported in the market include Abbott Laboratories, AbbVie, Inc., Bayer Pharma AG, Hisamitsu Pharmaceutical Co., Inc., Novartis AG, Novo Nordisk A/S, Orion Pharma AB, Pfizer, Inc., Meda pharmaceuticals, Teva Pharmaceutical Industries Ltd. and TherapeuticsMD, Inc., etc

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.